Stone X Group Inc. Astrazeneca PLC Transaction History

Stone X Group Inc.

$2.29 Trillion
Q3 2025

A detailed history of Stone X Group Inc. transactions in Astrazeneca PLC stock. As of the latest transaction made, Stone X Group Inc. holds 2,644 shares of AZN stock, worth $236,373. This represents 0.01% of its overall portfolio holdings.

Number of Shares

2,644

Holding current value

$236,373

% of portfolio

0.01%

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$68.72 - $82.11 $181,695 - $217,098	2,644 New	2,644 $203 Million
Q1 2025 Aug 13, 2025	BUY	$65.37 - $77.96 $199,117 - $237,466	3,046 New	3,046 $224 Million
Q1 2022 May 11, 2022	SELL	$55.72 - $67.12 $211,680 - $254,988	-3,799 Closed	0 $0
Q4 2021 Aug 13, 2025	BUY	$54.02 - $63.83 $205,221 - $242,490	3,799 New	3,799 $221,000
Q4 2021 Feb 10, 2022	BUY	$54.02 - $63.83 $205,221 - $242,490	3,799 New	3,799 $221,000

Q3 2021 Oct 20, 2021	SELL	$55.56 - $60.79 $1.94 Million - $2.13 Million	-35,005 Closed	0 $0
Q2 2021 Aug 06, 2021	BUY	$48.42 - $60.18 $1.69 Million - $2.11 Million	35,005 New	35,005 $2.1 Million
Q3 2017 Nov 13, 2017	SELL	$28.96 - $34.0 $942,619 - $1.11 Million	-32,549 Closed	0 $0
Q2 2017 Aug 31, 2017	BUY	N/A	32,549	32,549 $1.11 Million

Others Institutions Holding AZN

# of Institutions

1,502

Shares Held

500M

Call Options Held

5.64M

Put Options Held

3.2M

Price T Rowe Associates Inc Baltimore, MD

49.1M
Shares

$4.39 Billion
0.4% of portfolio
Primecap Management CO Pasadena, CA

39.9M
Shares

$3.56 Billion
2.42% of portfolio
Bank Of America Corp Charlotte, NC

32.6M
Shares

$2.92 Billion
0.18% of portfolio
Wellington Management Group LLP Boston, MA

32.3M
Shares

$2.89 Billion
0.45% of portfolio
Capital International Investors Los Angeles, CA

25.1M
Shares

$2.24 Billion
0.33% of portfolio

View Full List

About ASTRAZENECA PLC

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $277B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

More about AZN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Stone X Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Stone X Group Inc. with notifications on news.

Account